Novel Treatment Approaches in Higher-Risk Myelodysplastic Syndromes

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes.

In this video, Olatoyosi Odenike, MD, of the University of Chicago Medicine, reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes (MDS).

Odenike gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Related Videos
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024
Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Data Show Improved Posttransplant Outcomes in Elderly AML Population

April 10th 2024
Article

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study

Optimizing GVHD Prophylaxis: Exploring Intermediate-Dose PTCy in Bone Marrow Transplantation for Older Patients - Insights from Dr. Mustafa Hyder, MD's Study

March 27th 2024
Article

Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.

Geographic/Financial Barriers to CAR T Therapy Exist in Hematologic Cancers

March 20th 2024
Article

Findings suggest investigating an individualized monitoring period for stable patients with hematologic cancers to decrease financial and geographic barriers to CAR T-cell therapy.